Who are TERLIPRESSIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DDAVP, Vasopressin administration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/terlipressin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TERLIPRESSIN — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TERLIPRESSIN (TERLIPRESSIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin Receptor Agonist [EPC].

marketed Vasopressin Receptor Agonist [EPC] Recombinant protein Live · refreshed every 30 min

Target snapshot

TERLIPRESSIN (TERLIPRESSIN).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TERLIPRESSIN TARGET	TERLIPRESSIN		marketed	Vasopressin Receptor Agonist [EPC]		2022-01-01
DDAVP	DDAVP	Chang, Steve S., M.D.	marketed	Vasopressin receptor agonist	V2 vasopressin receptor (AVPR2)
Vasopressin administration	Vasopressin administration	Assistance Publique Hopitaux De Marseille	phase 3	Vasopressin receptor agonist	V1A and V2 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin Receptor Agonist [EPC] class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TERLIPRESSIN — Competitive Intelligence Brief. https://druglandscape.com/ci/terlipressin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing